Search
Clinician Ordering Portal
On-demand education
Understanding IDgenetix®
Jun 2021
Incorporating DecisionDx-Melanoma into Clinical Practice: Molecular Information for Personalized Management Decisions
Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients with Barrett’s Esophagus
Jun 2020
A risk prediction test identifies patients with non-dysplastic Barrett's esophagus who are at high risk for progression to high-grade dysplasia or cancer.
Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Non-Dysplastic Barrett’s Esophagus: A Spatial-Temporal Analysis
Oct 2020
Assessing additional spatial and temporal biopsies increased the predictive accuracy, allowing for identification of most future progressors.
Castle Biosciences Genomic Testing for Uveal Melanoma
Gene Expression Profiling: A Diagnostic Ancillary Test To Aid In The Diagnosis Of Melanocytic Lesions
Dr. Barry White shares cases of challenging melanocytic lesions in which gene expression profiling (GEP) was utilized to inform the diagnosis when histopathological findings were insufficient to render a definitive diagnosis
Utility of GEP in Difficult to Diagnose Melanocytic Lesions
Dr. Drazen Jukic presents challenging cases in which gene expression profiling (GEP) was utilized to inform the diagnosis of ambiguous melanocytic lesions.
Prediction of Progression in Barrett’s Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies
Feb 2022
Across all analyses, TissueCypher was the strongest and most significant predictor of progression to HGD or EAC.
Barrett’s Esophagus Panel: Predicting Progression in Barrett’s Esophagus Recent Advances Webinar
A panel discussion on the clinical challenges associated with predicting progression to esophageal adenocarcinoma in patients with Barrett’s esophagus.
Risk Stratification and Management of Dysplastic Barrett’s Esophagus
Jun 2022
Risk stratification is important in managing BE patients and biomarker assays such as TissueCypher® are “ready for Prime Time” in identifying patients at high risk for progression.
TissueCypher® Objectively Risk Stratifies Barrett’s Esophagus Patients with Low-Grade Dysplasia*
Pathologic diagnosis is highly variable, even among experts, while TissueCypher® provides objective risk stratification. TissueCypher outperformed community and expert pathologists for sensitivity and detected >50% of NDBE progressors who were down-staged (i.e. missed).
Barrett’s Esophagus Panel: Establishing Individual Patient Risk for Progression to Esophageal Cancer
Understand how TissueCypher® predicts future development of HGD/EAC in patients with BE. Impacts patient-care decisions as demonstrated by case studies.